. 2023 Jan 30;8(6):5234–5246. doi: 10.1021/acsomega.2c03881

Placebo Drug) in HEK293T Cells, Expressed as EC₅₀ Values in μM^a.

		inhibition of SARS-CoV-2 RdRp in vitro (EC₅₀ in μM)^b			respective ratios of EC₅₀
classification	compound name	Nsp12	Nsp12 + Nsp14	Nsp12 + Nsp14_mutant	(Nsp12 + Nsp14)/Nsp12	(Nsp12 + Nsp14_mutant)/Nsp12
target agent	S-217622	0.17 ± 0.02	0.27 ± 0.03	0.22 ± 0.03	1.59	1.29
reference drug	molnupiravir	0.24 ± 0.04	0.46 ± 0.06	0.35 ± 0.04	1.92	1.46
placebo solvent	DMSO	>100	>100	>100	N.A.^c	N.A.

nsp12 refers to the nsp12/7/8 complex, nsp14 refers to the nsp14/10 complex, and nsp14_mutant refers to the nsp14_mutant/10 complex.

EC₅₀ or 50% effective concentration is the concentration of the tested compound that is required for 50% reduction in the COVID-19 polymerase (SARS-CoV-2 RdRp) activity in vitro. EC₅₀ is expressed in μM.

N.A. means not available or not applicable (i.e., it was not determined).

Table 2. Anti-SARS-CoV-2-RdRp/ExoN Activities (along with Respective Ratios) of the Target Synthetic Compound S-217622 (Using Molnupiravir as the Positive Control/Reference Drug and DMSO as the Negative Control/Placebo Drug) in HEK293T Cells, Expressed as EC50 Values in μMa.

Table 2. Anti-SARS-CoV-2-RdRp/ExoN Activities (along with Respective Ratios) of the Target Synthetic Compound S-217622 (Using Molnupiravir as the Positive Control/Reference Drug and DMSO as the Negative Control/Placebo Drug) in HEK293T Cells, Expressed as EC₅₀ Values in μM^a.